\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ endocrine\\,\\ metabolic\\ or\\ toxic\\ abnormalities\\ were\\ identified\\.\ \(0\)\
\-\ there\\ is\\ no\\ treatment\\ for\\ fahr\\ disease\\.\ \(0\)\
\-\ symmetric\\ basal\\ ganglia\\ and\\ dentate\\ nucleus\\ calcifications\\.\ \(0\)\
\-\ fahr\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ benign\\ basal\\ ganglia\\ calcification\\ associated\\ with\\ aging\ \(0\)\
\-\ \\â\\€\\¢\\ endocrine\\:\\ hyper\\/hypoparathyroidism\\,\\ hypothyroidism\ \(0\)\
\-\ \\â\\€\\¢\\ metabolic\\:\\ \\ mitochondrial\\ disorders\ \(0\)\
\-\ \\â\\€\\¢\\ postinflammatory\\:\\ \\ tuberculosis\\,\\ toxoplasmosis\\,\\ cystercercosis\\,\\ congenital\\ hiv\\,\\ syphilis\ \(0\)\
\-\ \\â\\€\\¢\\ congenital\\:\\ \\ tuberous\\ sclerosis\\,\\ down\\ syndrome\\,\\ neurofibromatosis\ \(0\)\
\-\ \\â\\€\\¢\\ toxic\\:\\ \\ carbon\\ monoxide\\,\\ chemotherapy\\,\\ radiation\\ therapy\\,\\ lead\\ intoxication\ \(0\)\
\-\ 72\\ y\\.o\\.\\ woman\\ with\\ progressive\\ dementia\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ fahr\\:\\ 0\\.3406919021557099\ \(0\)\
\-\ endocrine\\:\\ 0\\.26345116108852895\ \(0\)\
\-\ toxic\\:\\ 0\\.24739862401454513\ \(0\)\
\-\ ganglia\\:\\ 0\\.22763948626515404\ \(0\)\
\-\ metabolic\\:\\ 0\\.21957031077620098\ \(0\)\
\-\ basal\\:\\ 0\\.2072535009911913\ \(0\)\
\-\ cystercercosis\\:\\ 0\\.18506132732472455\ \(0\)\
\-\ postinflammatory\\:\\ 0\\.174216601325571\ \(0\)\
\-\ congenital\\:\\ 0\\.1740265804855711\ \(0\)\
\-\ dentate\\:\\ 0\\.16707336292343675\ \(0\)\
\-\ mitochondrial\\:\\ 0\\.16423851811940687\ \(0\)\
\-\ aging\\:\\ 0\\.15747780899145072\ \(0\)\
\-\ intoxication\\:\\ 0\\.15393128412870938\ \(0\)\
\-\ monoxide\\:\\ 0\\.15089328179027983\ \(0\)\
\-\ carbon\\:\\ 0\\.14587479523026403\ \(0\)\
\-\ syphilis\\:\\ 0\\.14181873070061127\ \(0\)\
\-\ dementia\\:\\ 0\\.14181873070061127\ \(0\)\
\-\ nucleus\\:\\ 0\\.13689762871657138\ \(0\)\
\-\ toxoplasmosis\\:\\ 0\\.1361779055434102\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.12619982233724605\ \(0\)\
\-\ tuberous\\:\\ 0\\.12076640790494995\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.12009238937879797\ \(0\)\
\-\ hiv\\:\\ 0\\.11976323859426463\ \(0\)\
\-\ 72\\:\\ 0\\.11672523625583509\ \(0\)\
\-\ lead\\:\\ 0\\.10783609944810324\ \(0\)\
\-\ disorders\\:\\ 0\\.10692480931933926\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.10657097112288569\ \(0\)\
\-\ symmetric\\:\\ 0\\.10378003491845046\ \(0\)\
\-\ disease\\:\\ 0\\.10166905933726778\ \(0\)\
\-\ down\\:\\ 0\\.09837641670204363\ \(0\)\
\-\ progressive\\:\\ 0\\.09275149997596252\ \(0\)\
\-\ calcifications\\:\\ 0\\.08838343016052813\ \(0\)\
\-\ abnormalities\\:\\ 0\\.08772338320469693\ \(0\)\
\-\ calcification\\:\\ 0\\.08646183585280931\ \(0\)\
\-\ sclerosis\\:\\ 0\\.08625867831840962\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.08599079084800637\ \(0\)\
\-\ identified\\:\\ 0\\.08585810416398135\ \(0\)\
\-\ benign\\:\\ 0\\.08318924769839113\ \(0\)\
\-\ radiation\\:\\ 0\\.08025258111482939\ \(0\)\
\-\ no\\:\\ 0\\.07876231368457216\ \(0\)\
\-\ syndrome\\:\\ 0\\.0730080069578273\ \(0\)\
\-\ therapy\\:\\ 0\\.06958124383143988\ \(0\)\
\-\ associated\\:\\ 0\\.06383010191156213\ \(0\)\
\-\ woman\\:\\ 0\\.06307058089847077\ \(0\)\
\-\ were\\:\\ 0\\.062424842382276795\ \(0\)\
\-\ treatment\\:\\ 0\\.05768754934157132\ \(0\)\
\-\ there\\:\\ 0\\.04818631115673014\ \(0\)\
\-\ with\\:\\ 0\\.0474267692194965\ \(0\)\
\-\ or\\:\\ 0\\.04212940531535646\ \(0\)\
\-\ for\\:\\ 0\\.036705240037003116\ \(0\)\
\-\ is\\:\\ 0\\.03316474394122929\ \(0\)\
\-\ and\\:\\ 0\\.025024350138294325\ \(0\)\
